HUTCHMED Announced At ESMO Sunday, SAFFRON Phase III Shows ORPATHYS Plus TAGRISSO Cut Progression Or Death Risk 45%, Death Risk 32% Versus Chemotherapy In MET-Driven EGFR-Mutated Lung Cancer
Benzinga Newsdesk 5 days ago
News
ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —ORPATHYS plus TAGRISSO extended median OS
- ORPATHYS plus TAGRISSO reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO —
- ORPATHYS plus TAGRISSO extended median OS by nearly 5 months —
- SAFFRON is the first global Phase III trial to show significant progression-free and overall survival benefit in this setting —
- Establishes ORPATHYS plus TAGRISSO as an important targeted strategy to address MET-driven resistance following progression on prior EGFR TKI treatment —